A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis | MicrobiomeTrials
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2020-06-16Est. Completion: 2026-08-09
Enrollment target: 508 participants
Locations
As0014 50062, Glendale, Arizona, United States
As0014 50052, Phoenix, Arizona, United States
As0014 50060, Upland, California, United States
As0014 50059, Ormond Beach, Florida, United States
As0014 50056, Sarasota, Florida, United States
As0014 50015, Hagerstown, Maryland, United States
As0014 50016, St Louis, Missouri, United States
As0014 50055, Portland, Oregon, United States
As0014 50020, Duncansville, Pennsylvania, United States
As0014 50057, Dallas, Texas, United States
As0014 40004, Brussels, Belgium
As0014 40003, Genk, Belgium
As0014 40001, Ghent, Belgium
As0014 40006, Plovdiv, Bulgaria
As0014 40007, Plovdiv, Bulgaria
As0014 40005, Sofia, Bulgaria
As0014 40008, Sofia, Bulgaria
As0014 20040, Beijing, China
As0014 20021, Chengdu, China
As0014 20019, Guangzhou, China
As0014 20034, Hefei, China
Other microbiome trials you might be interested in